2014
Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass
Havrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. Journal Of The National Cancer Institute 2014, 107: dju322. PMID: 25515232, DOI: 10.1093/jnci/dju322.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsBiomarkers, TumorCA-125 AntigenCost-Benefit AnalysisDecision MakingDisease ManagementFemaleGenital Neoplasms, FemaleHumansMaleMarkov ChainsMedicareMembrane ProteinsMiddle AgedPostmenopausePractice Guidelines as TopicPremenopauseReferral and ConsultationRisk AssessmentSEER ProgramSensitivity and SpecificityUnited StatesWorkloadConceptsPostmenopausal womenAdnexal massesCutoff valueEnd Results-MedicareState Inpatient DatabasesGynecologists guidelinesBiomarker validation studiesPremenopausal womenClinical outcomesGynecologic oncologistsInpatient DatabaseMalignancy AlgorithmSurgical volumeReferral strategiesTriage strategiesMedical costsRelative survivalPhysician workloadCA125Test characteristicsCost-effective strategyWomenTest sensitivityAmerican CongressMedicare reimbursement
2012
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.Peer-Reviewed Original ResearchConceptsEstrogen receptor-positive breast cancerReceptor-positive breast cancerBreast cancerHormonal therapyClinicopathologic characteristicsRisk groupsEarly-stage breast cancerIncremental cost-effectiveness ratioHigh-risk characteristicsLifetime medical costsCost-effectiveness ratioLow-risk characteristicsDecision analytic modelChemotherapy useMedical costsChemotherapyPatientsHealth systemSocietal perspectiveRecurrenceCancerMultifactorial decisionTherapySupportive evidenceTreatment
2008
Effects of Disclosing Financial Interests on Attitudes Toward Clinical Research
Weinfurt KP, Hall MA, Dinan MA, DePuy V, Friedman JY, Allsbrook JS, Sugarman J. Effects of Disclosing Financial Interests on Attitudes Toward Clinical Research. Journal Of General Internal Medicine 2008, 23: 860-866. PMID: 18386101, PMCID: PMC2517900, DOI: 10.1007/s11606-008-0590-4.Peer-Reviewed Original Research
2006
Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and Investigators
Weinfurt KP, Friedman JY, Dinan MA, Allsbrook JS, Hall MA, Dhillon JK, Sugarman J. Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and Investigators. The Journal Of Law, Medicine & Ethics 2006, 34: 581-591. PMID: 17144182, PMCID: PMC1850937, DOI: 10.1111/j.1748-720x.2006.00072.x.Peer-Reviewed Original ResearchMeSH KeywordsAttitude of Health PersonnelBiomedical ResearchCommunication BarriersConflict of InterestDecision MakingDisclosureEthics Committees, ResearchHuman ExperimentationHumansInformed ConsentInterviews as TopicLiability, LegalOrganizational PolicyResearch SubjectsResearch Support as TopicTrustUnited StatesConceptsFinancial interestsConflicts of interestPotential research participantsInstitutional review board chairsInvestigators' financial interestsInterests of participantsResearch participantsBenefits of disclosureLegal liabilityInterest CommitteeResearch institutionsDisclosureConsent processConflictBoard chairsGeneral agreementInstitutionsDecisionsInterestLiabilityRightsGeneral attitudesRationaleReview boardCircumstances